Mouse Avatars: Innovative Approach Holds Promise For Personalizing Cancer Treatment
Executive Summary
Champions Oncology has developed TumorGraft, a novel predictive chemo-response technology that allows companies to simulate clinical trials, test anticancer drug regimens, and identify the regimens most likely to positively impact individual cancer tumors. For the clinical trial simulation capabilities alone, the technology has a market potential of $1.6 billion in the US, according to the company.